<DOC>
	<DOCNO>NCT02934568</DOCNO>
	<brief_summary>This study allow continue use ribociclib ( LEE011 ) single agent combination investigational treatment patient benefit treatment eligible Novartis-sponsored ribociclib ( LEE011 ) study reach primary objective ( ) halt reason .</brief_summary>
	<brief_title>Ribociclib ( LEE011 ) Rollover Study Continued Access</brief_title>
	<detailed_description />
	<criteria>1 . Patient currently enrol eligible Novartissponsored study receive ribociclib ( LEE011 ) single agent combination investigational treatment . 2 . Patient currently derive clinical benefit study treatment , determine investigator . 1 . Patient permanently discontinue ribociclib ( LEE011 ) parent protocol reason . 2 . Patients meet parent protocol criterion continue study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ribociclib</keyword>
	<keyword>LEE011</keyword>
</DOC>